Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ascorbic acid
Drug ID BADD_D00171
Description A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.
Indications and Usage Used to treat vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification, and in general as an antioxidant. It has also been suggested to be an effective antiviral agent.
Marketing Status approved; nutraceutical
ATC Code G01AD03; S01XA15
DrugBank ID DB00126
KEGG ID D00018
MeSH ID D001205
PubChem ID 54670067
TTD Drug ID D07AHW
NDC Product Code 63083-1505; 67157-101; 72783-1001; 63238-3000; 51552-0164; 49452-0742; 10695-126; 62512-0020; 51927-5098
UNII PQ6CK8PD0R
Synonyms Ascorbic Acid | Acid, Ascorbic | L-Ascorbic Acid | Acid, L-Ascorbic | L Ascorbic Acid | Vitamin C | Hybrin | Magnorbin | Sodium Ascorbate | Ascorbate, Sodium | Ascorbic Acid, Monosodium Salt | Ferrous Ascorbate | Ascorbate, Ferrous | Magnesium Ascorbate | Ascorbate, Magnesium | Magnesium di-L-Ascorbate | Magnesium di L Ascorbate | di-L-Ascorbate, Magnesium | Magnesium Ascorbicum
Chemical Information
Molecular Formula C6H8O6
CAS Registry Number 50-81-7
SMILES C(C(C1C(=C(C(=O)O1)O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tremor17.01.06.0020.000496%
Unresponsive to stimuli17.02.05.0310.000496%-
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.0010.002181%
Ventricular extrasystoles02.03.04.007---
Ventricular fibrillation02.03.04.0080.000496%
Vision blurred06.02.06.007; 17.17.01.0100.001090%
Vomiting07.01.07.0030.005006%
Multiple sclerosis relapse17.16.01.003---
Peripheral swelling02.05.04.015; 08.01.03.053---
Emotional distress19.04.02.0080.001239%-
General physical health deterioration08.01.03.0180.001487%-
Balance disorder08.01.03.081; 17.02.02.007---
Deep vein thrombosis24.01.02.0030.001239%-
Injection site swelling08.02.03.017; 12.07.03.018---
Skin burning sensation17.02.06.009; 23.03.03.021---
Haemorrhage24.07.01.0020.000991%-
Temperature intolerance08.01.09.0220.000496%-
Hypoaesthesia oral07.05.05.003; 17.02.06.021---
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.005--
Mental disorder19.07.01.002---
Neoplasm progression16.16.02.0050.000496%-
Decreased appetite08.01.09.028; 14.03.01.0050.001586%
Adverse drug reaction08.06.01.009---
Hypophagia07.01.06.010; 14.03.01.006; 19.09.01.004---
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Acute kidney injury20.01.03.0160.003470%
Renal tubular atrophy20.05.03.0220.000496%-
Tongue haemorrhage07.14.01.015; 24.07.02.058---
Crystal nephropathy14.11.01.035; 20.05.03.0160.003222%-
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages